Based on the binding mode of our previously discovered dual inhibitor of Bcl-2 and Mcl-1, 3-thiomorpholin-8-oxo-8H-acenaphtho[1,2-b]pyrrole-9-carbonitrile (3, S1), a library of 9-substituted 3 derivatives was synthesized to further probe the p4 pocket of the two targets. By NMR, structure-activity relationship study, and site-directed mutation, compound 6d (3-(4-aminophenylthio)-8-oxo-8H-acenaphtho[1,2-b]pyrrole-9-3-phenyl)propylamine) was identified to span p2-p4 pockets of Mcl-1, Bcl-2 and Bcl-x L , and then exhibited 9-to 35-fold better affinity to the three targets than 3 (IC 50 = 10, 20 and 18 nM, respectively), which led to greater activity in induction of apoptosis in multiple cancer cell lines. Different contribution of p4 pocket to binding Bcl-2 and Mcl-1 was also investigated by plotting the potency and the HAC of the derivatives.
Introduction
Targeting the interface between proteins has huge therapeutic potential, but discovering small molecule drugs that disrupt protein-protein interactions (PPIs) is an enormous challenge. 1, 2 Some notable successes were achieved with the discovery of BH3 mimetics. These molecules modulate the PPIs between anti-apoptotic and pro-apoptotic Bcl-2 members by occupying the BH3 groove shared by the two opposite functional groups and then induce cancer cells apoptosis. 3, 4 Although the BH3 grooves of Bcl-2 and Bcl-x L are the primary focus for the design of BH3 mimetics, 5 recent studies have demonstrated that Mcl-1 also plays an important role for cancer cell survival. It is necessary to neutralize both arms of the anti-apoptotic Bcl-2 family (Bcl-2/Bcl-x L and Mcl-1) for apoptosis to occur in many cell types. 6, 7 The most potent dual inhibitor (Bcl-2 and Bcl-x L ) ABT-737, for example, is encountering resistance due to the inability to bind a more divergent BH3 groove of Mcl-1 protein. 8, 9 As such, a promising drug-like BH3 mimetic should be a 'pan-Bcl-2 inhibitor' that can bind at least Bcl-2 and Mcl-1. 3 We have previously reported the discovery of a small-molecule Bcl-2 inhibitor, 3-thiomorpholin-8-oxo-8H-acenaphtho [1,2-b] pyrrole-9-carbonitrile (3, S1). [10] [11] [12] The in vivo apoptosis induction by 3 places it on the list of 19 preclinical Bcl-2 inhibitor antitumor drugs. 3 Further studies have described the biological mechanism of 3 as an authentic BH3 mimetic and a dual inhibitor that targets both Bcl-2 and Mcl-1. 11 In this study, the binding site of 3 was further confirmed by NMR and expanded to that of Bcl-x L .
Although the pan-Bcl-2 inhibition of 3 shows advantages over ABT-737, its affinity toward Bcl-2 (K i = 310 nM by fluorescence polarization assay (FPA)) is much less potent than ABT-737 (1 nM). 8 ABT-737 is a highly optimized ligand spanning the p2, p3 and p4 pockets which are sub-active sites in the BH3 groove. According to the X-ray structure of the Bim BH3 peptide in
Here, we designed series of derivates based on the binding mode of 3 which was further identified by NMR binding study in the present work. We maintained the p2 occupying and expanded to the p4. Many efforts were given to fit both Bcl-2 and Mcl-1 to maintain the dual inhibition. We discovered a new potent panBcl-2 inhibitor 3-(4-aminophenylthio)-8-oxo-8H-acenaphtho [1,2-b] pyrrole-9-(3-phenyl)propylamine (6d), which the IC 50 value to Mcl-1, Bcl-2 and Bcl-x L by ELISA was 10, 20 and 18 nM, respectively. The 9-to 35-fold better affinity was achieved for the three targets than its parent 3. Additionally, we defined the molecular determinants governing the specificity of ligand binding to the p4 pocket of Bcl-2 and Mcl-1.
Results and discussion

Rationale
We recently identified small-molecule 3 as an authentic BH3 mimetic and a dual inhibitor of Bcl-2 and Mcl-1. Herein, we included Bcl-x L in competitive binding test and found that 3 had similar binding affinities toward Bcl-x L with Bcl-2 (IC 50 = 625 and 710 nM, respectively by ELISA assay) ( Table 2 and Table S1 ). The broader binding profile confirmed 3 as a pan-Bcl-2 inhibitor. Because the three-dimensional structure of Bcl-2 is very similar with that of Bcl-x L but different with Mcl-1, we continuously focused on BH3 grooves of Bcl-2 and Mcl-1 for lead optimization.
SAR study determined that the carbonyl substitution of 3 binds near R263 of Mcl-1 and the homology of Bcl-2 termed R146 through hydrogen bonds. Its 3-position substituent extends into the p2 pocket, whereas the 9-position cyano group points to but does not access the p4 pocket of the two proteins (Fig. S1) . 12 To further identify the binding mode, here we performed a [ 15 N, 1 H] NMR titration study. In good agreement with the SAR results, the NMR spectra confirmed that 3 occupied the p2 and p3 pocket. The spectra of Mcl-1 alone (shown in blue) showed well-dispersed peaks, indicative of a folded and stable protein. Upon 3 addition, NMR spectra generated many chemical shifts (shown in red), which are indicative of tight binding (Fig. S2a) . The combined chemical shift perturbation (CCSP) signals revealed that more than 60% of the residues perturbed above 0.02 ppm were located in the BH3 binding groove of the protein (Fig. 1a) . Among them, some residues located in p2 and p3 pockets (V253, M250, R263, L246, F270 and K234) experience average chemical shift changes of at least 0.04 ppm (Fig. 1c ). There were several residues that experienced intensity reductions associated with line broadening. In particular, R263 and the nearing V253 had large intensity changes following the addition of 3, to a point where they were no longer detectable (Fig. S2b) . It supported the formation of the hydrogen bond in this area.
With the aim of accessing the p4 pocket to achieve enhanced dual inhibition effects, we designed series of 3 derivatives that the cyano group was replaced by longer and larger groups. Previous studies have reported that Bcl-2 and Mcl-1 show differences in the structure of their p4 pockets. 15 When we tried to occupy the p4, an optimization path should be carefully designed to resolve differences of the p4 between Bcl-2 and Mcl-1 without losing either one. At the outset, we aimed to maintain the binding mode with R263 in Mcl-1 and R146 in Bcl-2 constant since the key hydrogen bound was formed in this region. We then sought to the X-ray structure of the non-selective peptide Bim (BH3) in complex with Bcl-2-like proteins. The comparison of high-resolution structure study of Bcl-x L /Bim and Mcl-1/Bim showed that R263 in Mcl-1 is somewhat less solvent-exposed than its homologue in Bcl-x L . 16 Since Bcl-2 and Bcl-xL have quite similar structure with overall backbone RMSD (root mean square deviation) only 1.85 Å, 17 we concluded the R263 in Mcl-1 and its homologue in Bcl-2 might render an obvious difference in this region between the two proteins. Consistently, our computational modeling studies illustrated that the R263 of Mcl-1 was less solvent-exposed than R146 of Bcl-2 ( Fig. 2a and b 18 However, 3 contains one hydrogen bond available group. We proposed when the interaction with R263 or R146 was kept, a flexible linker group between the core structure of 3 and the p4-occupying group at 9-position should be chosen for the accommodation by both Bcl-2 and Mcl-1. Additionally, because Bim BH3 peptide utilized F69 to occupy p4 pocket, F69 becomes the mimicking goal of newly designed group to occupy p4. 19 Lastly, the molecular planarity and symmetry of the core of 3 has a general negative impact on solubility. Introduction of additional groups at 9-position would lead to the disruption of molecular planarity and symmetry, which could improve its solubility. 20 Thus, optimizing at 9-position of 3 could improve not only its binding potency, but perhaps also its solubility.
Structure-activity relationship
We initially substituted the cyano with amino as a linker group, which may render flexibility to compounds to allow them engage well into the p4 pocket of both Bcl-2 and Mcl-1. Meanwhile, amino could facilitate solubility by forming hydrogen bond with water. We sought to survey a variety of alkyl group in order to identify those win appropriate trajectory and length to access p4 pocket, meanwhile maintaining dual inhibition. Specifically, we examined ethylamine, n-propylamine, n-butylamine, n-pentylamine, and n-hexylamine groups, yielding analogues 3-thiomorpholin-8-oxo-8H-acenaphtho
pyrrole-9-n-pentylamine (5d) and 3-thiomorpholin-8-oxo-8H-acenaphtho [1,2-b] pyrrole-9-n-hexylamine (5e), respectively (Scheme 1). Different with parental 3, most of the 9-substituted derivatives have interruption to FPA by the autofluorescence. Thus, we took enzyme-linked immunosorbent assay (ELISA) to measure their abilities to competitively displace a Bim-derived peptide from Mcl-1 and Bcl-2, respectively. Triton X-100 was added as a detergent to prevent the possible aggregation of hydrophobic compounds, as described in the supporting information. The competitive binding curves of these compounds to Bcl-2 and Mcl-1 were outlined in Figure 3a and b. R-(À)-Gossypol was used as positive control.
14 Compound 3 was tested for comparison. While weaker binding affinity was found for 5a, better binding affinities than 3 toward Mcl-1 and Bcl-2 were found for 5b-5e. A progressive increase in length of the substituent (b < c < d < e) resulted in a corresponding increase in Mcl-1 and Bcl-2 affinity. Compound 5e exhibited IC 50 values of 37 and 96 nM for Mcl-1 and Bcl-2, respectively, which was nearly 3-and 7-fold more effective than 3 (IC 50 = 95 and 715 nM). We suspected that 5b have accessed p4 pocket and 5c, 5d, and 5e expanded inside the pocket.
Because 5b-5e were analogues with straight-chain substituent, we tried to replace the linear group with bulkier group to probe the surrounded areas between the arginine residue and p4. As such, we synthesized 5f and 5g with isopropyl and benzyl substitution, respectively. By ELISA, we found that 5f and 5g completely lost binding affinity to Bcl-2 (>10 lM), indicative of steric clashes in Bcl-2 protein. However, 5f retained a weak binding affinity to Mcl-1 (2.5 lM) and 5g showed a sub-micromolar affinity (521 nM). The different selectivity by these two compounds raised a possibility that the surrounded area at this position of Bcl-2 is different from that at Mcl-1. We calculated the width of this area by AutoDock tools, and found that the Bcl-2 R146 and Y108 residues narrowed the area by 8 Å, compared to the corresponding Mcl-1 R263 and H224 residues, which was 14.4 Å (Fig. S3 ). As such, Bcl-2 could not accommodate 5f and 5g with bulkier group. As for Mcl-1, it could accommodate the more conformationally restrained benzyl (5g) substitution but cannot accept the steric bulky isopropyl (5f) substitution. It was further confirmed by docking studies. As shown in Figure 4a and b, benzyl substituent of 5g was sterically repulsed by the R146 and Y108 residues of Bcl-2. By comparison, Mcl-1 could, to a certain degree, accommodate this substitution. Remarkably, though 5g could bind Mcl-1, its potency was about sixfold lower than that of 5c (79 nM) and 5d (37 nM), which have a similar substituent length with it, indicating that bulkier group in this area contributes less to or adversely affect binding affinity, especially for Bcl-2. On the basis of these data, we identified n-propyl, n-butyl, n-pentyl and n-hexyl as the proper groups to access the p4 because they could fit well within different BH3-binding grooves of Bcl-2 and Mcl-1.
We also explored the effect of rigid group on the dual inhibition by substituting the cyano with ester as the linker group. As expected, the conversion of amino group to a rigid ester negatively impacted the potency. Ethoxycarbonyl and n-propoxycarbonyl substitution yielded compounds 4a and 4b (Scheme 1) showed dramatically decreased affinities than 5c and 5d. No binding affinities to Mcl-1 (>10 lM) and very weak affinities to Bcl-2 (2.2 and 2.1 lM, respectively) were found for them. It is reasonable to attribute the loss of affinity to the rigid C-O-C@O, which formed a dihedral equal to 0°or 180°2 1 These results suggested a flexible linker are favorable for binding the two protein targets. Having optimized the linker with flexible and linear character, we now tried to utilize a benzene group to mimic the F69 of non-selective peptide Bim for occupying p4 pocket. Since 5b, 5c, 5d and 5e have accessed p4 pocket, we added benzene to the terminus of the alkyl chain of these compounds, yielding 3-thi-
pyrrole-9-(3-phenyl)pentylamine (5j) and 3-thiomorpholin-8-oxo-8H-acenaphtho[1,2-b]pyrrole-9-(3-phenyl) hex ylamine (5k). In ELISA assay, 5h exhibited the most potent binding affinity to Bcl-2 (49 nM) and Mcl-1(15 nM), which achieved nearly 12-and 6-fold better affinities toward Bcl-2 and Mcl-1, respectively than 5b. Compound 5i also showed about 2-to 3-fold improved affinities than 5c. However, 5j exhibited a significant decrease of binding affinities to Bcl-2 (1.3 lM) and Mcl-1(1.1 lM) compared to 5d. Compound 5k showed a similar loss of affinity. In agreement with it, docking results of 5h and 5j showed that 3-phenylpropyl was properly located in the p4 pocket of Mcl-1, while the 3-phenylpentyl of 5j was repulsed out by the p4 pocket ( Fig. 4c and d) . Therefore, an alkyl group with three carbons was the optimal length to mimic the northern part of D67 to F69 of Bim peptide.
In our previous SAR study, aminophenylthio group at the 3-position was identified to fit p2 better than thiomorpholin. Methoxyphenylthio and isopropylphenoxy were groups that could fit p2 but not as well as thiomorpholin. 12 In order to discover more potent inhibitors by spanning p2 and p4, and gain insights into the druggability of the p2 and p4 pockets, we selected 3-(4-aminophe-
carbonitrile (7a) and 3-(4-isopropylphenoxy)-8-oxo-8H-acenaphtho[1,2-b]pyrrole-9-carbonitrile (8a) as starting compounds for further optimization at 9 position. Series 6 (6a-6d), 7 (7a-7d), and 8 (8a-8d) were synthesized (Table 1) . We found that butyl, hexyl and 3-phenylpropyl substitution brought about a corresponding increase of binding affinity to Bcl-2 and Mcl-1 in the three series (Tables 1 and 2 ), which was in agreement with the results of 5c, 5e and 5h. Comparably, the rank order of binding affinities for certain 9-substituted analogues from series 5, 6, 7 and 8 was keeping the same as the rank order of p2-occupying efficiency, which is 6a > 3 > 8a > 7a. We also tested the binding affinities of 3 derivatives toward Bcl-x L and gained the same trend of improvement (Table S1 ). Among them, the most potent 6d displayed IC 50 values of 10, 20 and 18 nM for Mcl-1, Bcl-2 and Bcl-x L , respectively, which is 9-35 times more effective than 3. To confirm the results of the ELISA assay data, we also performed isothermal titration calorimetry (ITC) assay with 6d and 3 in parallel. In consistent with the improvement in IC 50 values, 6d exhibited a K d value of 105 nM, which was about ninefold improved than that of 3 (K d = 964 nM, Fig. 5 ).
Identification of binding site by site-directed mutagenesis and NMR
R263 of Mcl-1 and the R146 of Bcl-2 have been determined to form a hydrogen bond with carbonyl of 3. To examine whether R263 still played an important role in the binding of newly designed 3, 9 substituted 3 derivatives, we constructed a site-directed mutant on R263A and evaluated the binding affinities of some representative analogues toward wild-type Mcl-1 and Mcl-1 R263A mutant, respectively by using ITC. 6d, for example, showed a 20-fold lower affinity toward R263A mutant (2.34 lM, Table 3 and Fig. S4 ) than wild-type Mcl-1. The similar decrease was found for other compounds (Table 3) . It supported that R263 still served as an anchor residue by forming hydrogen bond network with 3, 9 substituted 3 derivatives. Together with the same rank order of p2-occupying efficiency, we proposed that these derivatives gained increased affinity by additional occupation of p4 pocket when maintained the p2 occupation.
To further determine the binding site, we produced uniformly 15 N-labeled Mcl-1 protein and performed NMR titration by 6b, because 6b is more soluble than 6d in Mcl-1 solution. We measured two-dimensional [ 15 N, 1 H] NMR spectra in the absence and presence of 6b, respectively. Figure S2c showed an overlay of the spectra before (blue) and after (red) the addition of 6b, (Fig. 1a) , a same cluster of residues in p2 including R263, V253, L246, M250, F270 and K234 experienced average chemical shift changes of at least 0.05 ppm (Fig. 1b) . Notably, another cluster of residues including V220, R215, V216 and G219 which experienced at changes of at least 0.06 ppm emerged after adding 6b. In particular, R263 and V216 are no longer detectable. Mapping these residues into 3D structure of Mcl-1 showed their locations within and surrounding the p2 and p4 pocket (Fig. 1d) . So far, we identified that 6b occupied p2 and p4 simultaneously.
Comparing the different contribution of p4 to binding affinity between Bcl-2 and Mcl-1
The alanine scanning studies have shown when F69 of Bim was mutated to alanine, it lost most of the affinity to Bcl-x L. However the mutant can still bind Mcl-1 in the same range even it lost p4 occupation. 22 Additionally, a broader p4 pocket in Mcl-1 than that in Bcl-2 has been revealed by a molecular dynamics study. 15 These studies suggested that the p4 pocket has less contribution to Mcl-1 binding. In the present study, however, we found binding affinities to Mcl-1 were progressively improved accompanied with increased p4 occupation. We inferred that p4 occupying was still a dominant contributor for a molecule to bind to Mcl-1. Notably, for an optimized compound, it was improved less dramatically for Mcl-1 (average eightfold) than for Bcl-2 (average 17-fold), such as compound 5h, 6d, 7d, and 8d. It suggested the contribution of p4 was different between the two proteins.
To further illustrate the contribution of p4 occupation to Bcl-2 and Mcl-1, respectively, we calculated the contribution of p4-occuping groups per atom by plotting the potency against the HAC in serials 5, 6, 7, and 8. When a certain 3-position substituent was chosen to occupy p2, groups with an increased size were substituted at 9-position to occupy p4. As shown in Figure 6a for Mcl-1, a linear relationship between potency and HAC was found for compounds 3, 5c, 5e and 5h. When plotted with the other serials, nearly parallel trend lines were found, with an average value for the slop of 0.16 kcal mol À1 per heavy atom. These data implied that the parental core remained unchanged and that the 9-position substituent was simply added the p4 occupation. Given the constancy of slop in different serials, the same binding efficiency of 0.16 should be directly related to the contribution of p4 in Mcl-1. As for Bcl-2, co-linear relationships between potency and HAC were also found in the four serials. However, the average value for the slop was approximately 0.21 kcal mol À1 per heavy atom. It suggested that additional groups to occupy p4 contributed less affinity to Mcl-1 than Bcl-2. From the aspect of p4 pocket, the binding site of Bcl-2 might be more druggable than that of Mcl-1.
Improved solubility of 3, 9 substituted 3 derivatives
Next, we tested the solubility of 3, 6b and 6d in 1% DMSO/H 2 O which has been accepted to be orally and intravenously available for drug treatment in vivo. 23 As shown in Tables 4 and 3 was practically insoluble (0.002 mg/mL) in this solvent, while the solubility of 6b and 6d could reach 0.027 and 0.018 mg/mL, respectively. The increase of solubility showed the improved drug-like properties compared to 3. 
Mcl-1+ 6d
Mcl-1+ 3 Figure 5 . Bcl-2, that is, human chronic myelogenous leukemia cell line K562, myeloid leukemia cell line HL-60 and breast cancer cell line MCF-7. Among them, K562 and HL-60 express the highest level of Mcl-1 and Bcl-2, respectively (Fig. 7a) . By co-immunoprecipitation (Co-IP) assays, we found that 6b and 6d exhibited greater potential than 3 to disrupt Bcl-2/Bax and Mcl-1/Bak complexes. Meanwhile, the compounds released cytochorme c to cytosome in the same order as the complexes disruption ( Fig. 7b and c) . These data demonstrated that 6b and 6d exhibited enhanced apoptosis induction than 3 through disrupting complexes of Bcl-2 and Mcl-1. Compound 3 has been identified as a pure BH3 mimetic that kills via Bax/Bak completely. Most of the recently developed nanomolar inhibitors (six of seven) such as Gossypol (BL-193, AT-101) are not pure BH3 mimetics and then showed unexpected toxicity. 8, 24 Next, we determined whether or not 6b and 6d retained the property of 3 as a pure BH3 mimetic. Bax and Bak was both silenced in MCF-7 cells by shRNA (Fig. S5) . Gossypol was used as a negative control. After 12 h of exposure to 5 lM of compounds, cytochrome c release was examined. In contrast with cytochrome c release in wild-type MCF-7 cells, no cytochrome c release was found for 3, 6b and 6d in Bax-and Bak-deleted cells. However, the same amount of cytochrome c release as that in wild-type cells was detected for Gossypol ( Fig. 7d and e) . This strongly supported that 6b and 6d killed completely dependent on Bax/Bak. The pure Table 1 . BH3 mimicking property of these derivatives could render them an attractive aspect in the future clinical development.
Conclusions
We substituted the 9-position of 3 to probe the different p4 pockets in Bcl-2 and Mcl-1. [ 15 N, 1 H] NMR, SAR studies and site-directed mutation determined that when the key interaction with R263 in Mcl-1 and its homologue in Bcl-2 was maintained constant, flexible amino liker made derivatives accepted by the different angle of the BH3 groove of two proteins in the p4 region. Additionally, a broader space between R263 and p4 of Mcl-1 than that of Bcl-2 was identified by small molecules. Ultimately, the most potent compound 6d that contained a three-carbon alkyl group to optimally mimic the northern part of D67 to F69 of Bim peptide and utilized the terminal benzene to mimic F69, exhibited 9-to 35-fold improvement than 3 with IC 50 values of 10, 20 and 18 nM toward Mcl-1, Bcl-2 and Bcl-x L , respectively. Excitingly, its improved binding affinity also translated to greater potency of disrupting Bcl-2/Bax and Mcl-1/Bak complex in cells, resulting in enhanced apoptosis induction in multiple cancer cell lines with variant Mcl-1 and Bcl-2 expression levels. Together with pure BH3 mimicking property and improved solubility than 3, 6b and 6d represent novel potent lead drugs for cancer therapy.
In addition, we showed co-linear relationships of potency against the HAC by 9-position substituted derivatives with the slop of 0.16 and 0.21 kcal mol À1 per heavy atom for Mcl-1 and Bcl-2, respectively. It suggested that p4 occupying could contribute to dual Bcl-2 and Mcl-1 inhibitor, but the contribution was less for Mcl-1 than Bcl-2.
Experimental
Chemistry
The synthesis of 6b and 6d is shown in Supplementary data Scheme 3. 6b. Yield: 23%. 
ELISA assay
An enzyme-linked immunosorbent assay was reported as previous. For this assay, BiotinylatedBim peptide (residues 81-106,
hereafter called biotin-Bim) was diluted to 0.09 lg/mL in SuperBlock blocking buffer in PBS (Pierce Biotechnology, Inc, Rockford, IL, catalog # 37515) and incubated for 1.5 h in 96-well microtiter plates already coated with streptavidin (Qiagen, Catalog # 15500) to allow the formation of the complex between Biotin-Bim and streptavidin. All incubations were performed at room temperature unless otherwise noted. Each inhibitor was first dissolved in pure DMSO to obtain a 10 mM stock solution. Next, serial dilutions of compounds with 0.01% Triton X-100 were incubated with 20 nM protein in PBS for 1 h. The plates were washed three times with PBS containing 0.05% Tween-20.
The inhibitor and protein mixture (100 lL) were transferred to the plate containing the biotin-Bim/streptavidin complex and incubated for 2 h. The plate was then washed as before and mouse anti-His antibody that conjugated with horseradish peroxidase (Qiagen, Catalog # 34460) was added into the wells and incubated for 1 h. The plate was then washed with PBS containing 0.05% Tween-20. Finally, TMB (100 lL, Beyotime, Catalog # P0209) was added to each well; the enzymatic reaction was stopped after 30 min by addition of H 2 SO 4 (100 lL, 2 M). Absorbances were measured with a TECAN GENios (Swiss, TECAN) microplate reader using a wavelength of 450 nm. Three independent experiments were performed with each inhibitor to calculate average IC 50 value and standard deviation (SD).
ITC assay
Isothermal titration calorimetry (ITC) was performed using iTC200 (Microcal). Experiments were performed in 20 mM Tris pH 8.0, 150 mM NaCl, 1% DMSO at 25°C. For evaluating K d value of 6d compared with that of 4, titrations consisted of 12 Â 3 lL injections of compound at 300 lM into Mcl-1 (30 lM). For evaluating K d values of analogues toward wild-type Mcl-1 compared with that toward Mcl-1 R263A, titrations consisted of 16 Â 2.5 lL injections of compound at 500 lM into Mcl-1 (50 lM). All sample data obtained after control data corrections were analyzed to fit to a one-site model. For control ITC experiments, the sample cells were filled with assay buffer and the compound solution was added. This process was identical to that for protein samples. 
NMR spectroscopy
